Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EuroapiXPAR:EAPI -0.12%54 Price-to-Operating-Cash-Flow is 0.64 as of Sep. 06, 2026, which is 97% below its 10-year median of 20.69. GuruFocus rates XPAR:EAPI with a GF Score™ of 54/100 and a GF Value™ of €2.81 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 700 Drug Manufacturers companies, Euroapi ranks better than 99.43% on this metric.
As of today (2026-09-06), Euroapi's share price is €0.866.
Euroapi's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2025 was €1.35. Hence, Euroapi's Price-to-Operating-Cash-Flow Ratio for today is 0.64.
The historical rank and industry rank for Euroapi's Price-to-Operating-Cash-Flow or its related term are showing as below:
XPAR:EAPI'
s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 0.64 Med: 20.69 Max: 128.57
Current: 0.64
During the past 7 years, Euroapi's highest Price-to-Operating-Cash-Flow Ratio was 128.57. The lowest was 0.64. And the median was 20.69.
XPAR:EAPI's Price-to-Operating-Cash-Flow is ranked better than 99.43% of 700
companies
in the Drug Manufacturers industry
Industry Median: 16.025
vs XPAR:EAPI: 0.64
Euroapi's Cash Flow from Operations per share for the
six
months ended in Dec. 2025 was €1.16.
Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2025 was €1.35.
During the past 12 months, the average Operating Cash Flow per Share Growth Rate of Euroapi was 4.20% per year.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 42.10% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 2.30% per year.
During the past 7 years, Euroapi's highest 3-Year average Operating Cash Flow per Share Growth Rate was 42.10% per year. The lowest was -62.80% per year. And the median was 14.00% per year.
Euroapi Price-to-Operating-Cash-Flow Related Terms
Euroapi Price-to-Operating-Cash-Flow Historical Data
* Premium members only.
The historical data trend for Euroapi's Price-to-Operating-Cash-Flow can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:EAPI vs ZTS, UTHR, VTRS: Price-to-Operating-Cash-Flow Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Euroapi's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Euroapi Price-to-Operating-Cash-Flow vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Euroapi's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Euroapi's Price-to-Operating-Cash-Flow falls into.
Euroapi's Price-to-Operating-Cash-Flow ratio for today is calculated as
Price-to-Operating-Cash-Flow Ratio
=
Share Price
/
Cash Flow from Operations per share (TTM)
=
0.866
/
1.353
=
0.64
Euroapi's Share Price of today is €0.866.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Euroapi's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2025 was €1.35.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Price-to-Operating-Cash-Flow of 0.64 mean?
Euroapi (XPAR:EAPI) has a Price-to-Operating-Cash-Flow of 0.64 as of Sep. 06, 2026. Price-to-operating-cash-flow ratio is the ratio of share price to a company's per-share cash from operations. View historical data on Euroapi and its competitors. This is 97% below median its historical median of 20.69. Over the past decade, Euroapi's Price-to-Operating-Cash-Flow has ranged from 0.64 to 128.57. According to the industry distribution chart, Euroapi ranks #4 out of 700 companies in the Drug Manufacturers industry, placing it in the top 0.59999999999999%.
Is Euroapi's Price-to-Operating-Cash-Flow too high?
Euroapi's current Price-to-Operating-Cash-Flow of 0.64 is 97% below median its 10-year median of 20.69. Over the past 10 years, this metric has ranged from a low of 0.64 to a high of 128.57. The Drug Manufacturers industry median Price-to-Operating-Cash-Flow is 16.03. Euroapi's value of 0.64 is 96% below this industry median. Based on the distribution chart, Euroapi ranks #4 out of 700 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Euroapi has a GF Score™ of 54/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Euroapi's Price-to-Operating-Cash-Flow compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Euroapi ranks #4 out of 700 companies for Price-to-Operating-Cash-Flow. This places Euroapi in the top 1% of its industry — outperforming the majority of peers. The industry median Price-to-Operating-Cash-Flow is 16.03. Euroapi's value of 0.64 is 96% below this benchmark. Historically, Euroapi's own Price-to-Operating-Cash-Flow has ranged from 0.64 to 128.57 over the past decade. While the company's 10-year median is 20.69 vs. the industry median of 16.03, Euroapi has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Operating-Cash-Flow for a Drug Manufacturers company?
The median Price-to-Operating-Cash-Flow among Drug Manufacturers companies is 16.03, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Operating-Cash-Flow significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Operating-Cash-Flow should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Euroapi's current Price-to-Operating-Cash-Flow of 0.64 is 96% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Operating-Cash-Flow mean?
A high Price-to-Operating-Cash-Flow can signal that a stock is expensive relative to its fundamentals. Price-to-operating-cash-flow ratio is the ratio of share price to a company's per-share cash from operations. View historical data on Euroapi and its competitors. For the Drug Manufacturers industry, the median Price-to-Operating-Cash-Flow is 16.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Euroapi's current Price-to-Operating-Cash-Flow is 0.64, which is 97% below median its own 10-year median of 20.69. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Euroapi stock overvalued right now?
Based on GuruFocus' analysis, Euroapi (XPAR:EAPI) is currently considered Possible Value Trap. The stock's GF Value™ is €2.81, compared to a current price of €0.87 — trading 69.2% below its estimated fair value. The current Price-to-Operating-Cash-Flow is 0.64, which is 97% below median its 10-year median of 20.69 and 96% below the Drug Manufacturers industry median of 16.03. Euroapi's overall GF Score™ is 54/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Operating-Cash-Flow calculated?
Price-to-Operating-Cash-Flow is calculated from a company's financial statements. For Euroapi (XPAR:EAPI), the current Price-to-Operating-Cash-Flow is 0.64 as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Euroapi (XPAR:EAPI) Overvalued in 2026?
Based on GuruFocus' analysis, Euroapi stock appears to be undervalued.
The current stock price of €0.87 is trading 69.2% below its estimated GF Value™ of €2.81.
GuruFocus considers Euroapi to be Possible Value Trap.
Key valuation signals for XPAR:EAPI:
Price-to-Operating-Cash-Flow: 0.64 (97% below median its 10-year median of 20.69)
GF Value™: €2.81 vs. price of €0.87 (69.2% below fair value)
Industry Position: 96% below the Drug Manufacturers median (#4 of 700)
No single metric tells the full story. See the XPAR:EAPI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Euroapi SA develops, manufactures, markets, and distributes Active Pharmaceutical Ingredients (APIs) and Intermediates used in the formulation of medicines for human and veterinary use, both from originators, generics, and cosmetics. The company offers vitamin B12, prostaglandins, oligonucleotides, peptides, corticoids and hormones, anti-infectives, opiates, analgesics, and others. It also offers Contract Development Manufacturing Organization (CDMO) services to its customers.
54GF Score
Get the complete analysis for XPAR:EAPI
Price-to-Operating-Cash-Flow is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:EAPI has been successfully added to your 
